Real-world rivaroxaban study 'confirms safety'

Rivaroxaban has a favourable safety in real-world practice, according to a large prospective study.

More than 11,000 patients with AF from 47 countries prescribed rivaroxaban (Xarelto) for stroke prevention were followed for a year in the pooled XANTUS study, which had no comparator arm and was funded by the manufacturer, Bayer.

Major bleeding occurred at a rate of 1.7 events/100 patient years, with fatal bleeding, critical organ bleeding and intracranial haemorrhage occurring at 0.2, 0.6 and 0.4 events/100 patient years respectively.